Actinium faces potential securities fraud investigation after FDA deems Phase 3 trial insufficient, causing stock drop.

Actinium Pharmaceuticals faces a potential securities fraud investigation by Pomerantz LLP following a negative FDA update on its planned BLA filing for Iomab-B in r/r AML. The Phase 3 SIERRA trial was deemed insufficient for BLA filing. After the announcement, Actinium's stock dropped 59.81%. Pomerantz LLP advises investors to contact them for further info.

August 27, 2024
53 Articles

Further Reading